Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.59 |
| ▸ | HTR3B | O95264 | 2/20 | 0.59 |
| ▸ | HTR3A | P46098 | 2/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221269 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4453290 | 0.80 | MEN1 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1786140 | 0.80 | MEN1 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12338150 | 0.79 | CHRNA7 (0.66) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31196944 | 0.79 | CHRNA7 (0.65) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4152261 | 0.79 | CHRNA7 (0.65) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7302350 | 0.78 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7295304 | 0.78 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31000129 | 0.77 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29893635 | 0.77 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133184-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | ANIONA APS (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133184-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | ANIONA APS (DK) | 2015-09-15 | — | — | US | disclosed |
| US-20140235669-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2014-08-21 | — | — | US | disclosed |
| US-20140235669-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2430020-B1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2013-10-09 | — | — | EP | disclosed |
| US-20130040985-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-20130040985-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-8263617-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| US-8263617-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-1989202-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2012-07-25 | — | — | EP | disclosed |
| EP-2121677-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEURO SEARCH A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEURO SEARCH A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20090312364-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-12-17 | — | — | US | disclosed |
| US-20090312364-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-12-17 | — | — | US | disclosed |
| WO-2008074798-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074797-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007093604-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC6A2 | CHRNA7 68/4885HTR3E 83/4885HTR3B 22/4885 |
| US-20130040985-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC18A3 | CHRNA7 37/4885HTR3E 53/4885HTR3B 20/4885 |
| US-20090312364-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | CHRNA7 76/4885HTR3E 63/4885HTR3B 20/4885 |
| US-20140235669-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC18A3 | CHRNA7 37/4885HTR3E 53/4885HTR3B 20/4885 |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | CHRNA7 76/4885HTR3E 63/4885HTR3B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.